

Letter to the Editor:

Pro-cognitive effect of a prebiotic in psychosis: A double blind placebo controlled cross-over study.

Amy Chia-Ching Kao¹, Jana Safarikova², Tahnee Marquardt², Bradley Mullins², Belinda R Lennox¹,
Philip WJ Burnet^{1*}

¹Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, United Kingdom

²Research & Development Department, Oxford Health NHS Foundation Trust, Warneford Hospital,
Oxford OX3 7JX

*Address correspondence to: phil.burnet@psych.ox.ac.uk

Philip Burnet, PhD

Department of Psychiatry

University of Oxford

Warneford Lane

Oxford, OX3 7JX

Word count (text only): 995/1000

References: 10/15

Cognitive impairments in psychosis are highly disabling, and are detectable even at first episode of illness, and remain stable or deteriorate for periods of up to ten years (Bozikas and Andreou, 2011). While cognitive improvement is a key predictor of functional recovery, weight gain is also a common side-effect of antipsychotics contributing to the increased prevalence of obesity in patients (Dickerson et al., 2006). Dietary supplementation with a prebiotic, (a substrate selectively utilized by beneficial gut bacteria), improves cognitive flexibility (Gronier et al., 2018) and prevents olanzapine-induced weight gain (Kao et al., 2018) in rats. These effects may have resulted from suppressed circulating pro-inflammatory factors such as C-Reactive Protein (CRP) and IL-6 (Vulevic et al, 2013), and/or from the beneficial actions of acetate produced from the bacterial fermentation of the prebiotic (Kao et al, 2018). The aim of the present study, was to examine whether the daily ingestion of the prebiotic, B-GOS®, improved cognitive function, attenuated weight gain and/or influenced circulating immune/metabolic markers in medicated, stable psychosis participants.

Ethical approval was provided by South-Central Oxfordshire Research Ethics Committee B (16/SC/0654). Thirty-nine non-hospitalised participants (18-60 years old) with psychosis, stable on antipsychotic medication for at least three months prior to recruitment, and whose global cognitive score was 0.5 standard deviations below the healthy average (see below), were randomized in a double-blind placebo-controlled crossover trial (Figure S1). Exclusion criteria for B-GOS® and placebo supplementation has been previously described (Schmidt et al, 2015). The study is registered on ClinicalTrials.gov (NCT03153046).

Participants performed the Brief Assessment of Cognition in Schizophrenia (BACS, Keefe et al., 2008), at baseline, 12 and 24 weeks, and results were expressed as a standardized T-score to

account for age and gender. The Token Motor Test was presented as a raw value. Subjects also completed the Becks Depression Inventory (BDI, Beck et al., 1961). Body mass index, waist-to-hip ratio, hip and waist circumference were assessed, and blood samples taken, at baseline, 12 and 24 weeks. Sera were stored at -80°C prior to measures of CRP, IL-6 and acetate concentrations using commercial assay kits (Abcam, UK).

All data were assessed for normality using the Shapiro-Wilk test (SPSS ver.22). Paired t-tests examined the overall effects of B-GOS® or placebo on pooled data before and after the administration of supplements. A linear mixed model repeated measures analysis explored the influence of group (placebo vs B-GOS®) and time (0 [baseline], 12 and 24 weeks) on all parameters. The level of significance was set at $p < 0.05$.

A significant increase in the composite T-score (effect size, *Cohen's d*=0.443) was observed following B-GOS® (n=24) intake, but not placebo (n=25) (Figure 1A, Tables S1, S2), whereas placebo improved verbal fluency alone (effect size, *d*=0.447, Table S2). To explore which particular domains led to the overall improvement in cognitive performance, the BACS subtests data were arranged into two groups: 'verbal' (verbal memory, verbal fluency) and 'executive' (digit sequencing [measures verbal working memory], symbol coding, Tower of London) functions. There was a significant pre- versus post- effect of B-GOS® on the executive, but not verbal, domains ($t = -2.114$, $p = 0.045$, $n = 24$, *d*=0.432, Figure S2A). Placebo had no influence on these domains (Figure S2B). The overall effect of B-GOS® on the composite T-scores, therefore, was driven by subtests of executive function.

Linear mixed model repeated measures revealed an overall significant effect of time on the BACS composite T-score in all participants ($F = 6.998$, $p < 0.05$). Estimates of fixed effects indicated that this

increase was significant at 0-12 weeks, ($t = -3.638$, $p < 0.05$, $n = 39$), and was driven by the improvement in patients supplemented with B-GOS® (Figure 1B; $t = -2.410$, $p = 0.033$, $n=13$), but not in those receiving placebo ($t = -1.443$, $p = 0.186$, $n=14$). The calculated effect size for B-GOS® in this part of the study was $d = 0.669$. Analysis of the 12-24 week period revealed a non-significant increase in composite T-scores in patients taking the prebiotic, whereas a decrease was observed in the placebo group (Figure 1B). The overall change in T-scores between 0-24 weeks was only significant in subjects completing the trial with the prebiotic (Figure 1B). A similar analysis of verbal fluency T-scores, (in view of the placebo effect, Table S2), revealed a trend overall effect of time ($F = 3.026$, $p = 0.07$), but no significant fixed effects at 0-12 weeks or 12-24 weeks ($p > 0.05$). The placebo finding therefore, may have occurred by chance and an upshot of the 'learning effect' observed after repeated cognitive testing (Figure 1B). There were no significant differences in mood, anthropometric indices or serum levels of acetate, CRP and IL6 after B-GOS® (Table S1) or placebo (Table S2).

The B-GOS®-mediated improvement in global cognition in participants with psychosis is a novel finding, and is consistent with previous work demonstrating improved cognitive flexibility in rats (Gronier et al., 2018), and attentional vigilance in healthy volunteers (Schmidt et al., 2015) following prebiotic intake. Neurocognitive impairment in psychosis has been hypothesized to originate from central N-methyl-D-aspartate receptor (NMDAR) hypo-function (Coyle, 2012). Given that B-GOS® elevates brain NMDARs and D-serine in rats (Kao et al., 2018; Savignac et al., 2013), their increase in psychosis patients may have mediated the enhancement in cognitive function.

The current study also demonstrated that B-GOS® supplementation did not affect weight, BMI, central adiposity or circulating candidate metabolic/immune markers. This is in contrast to our recent observation in rats, where B-GOS® administration attenuated olanzapine-induced weight gain (Kao et al., 2018). However, since a majority of participants had been treated for several years, it is possible that B-GOS® is ineffectual once olanzapine-induced metabolic side effects are established.

In conclusion, this investigation provides the first proof-of-concept that the consumption of the prebiotic B-GOS® confers significant cognitive benefits in medicated participants with psychosis, possibly driven by improvements in specific executive functions. Future studies to corroborate our findings and to test other prebiotics, should include clinical symptom assessments to reveal the overall therapeutic utility of prebiotics in psychosis, and measures of gut microbiome composition to define the associations between bacterial communities and cognition in participants.

Acknowledgements

This study was funded by University of Oxford internal funds (PWJ Burnet). ACC Kao is a recipient of the Clarendon Graduate Scholarship (University of Oxford).

Conflict of Interest

Clasado Biosciences Ltd provided the B-GOS® and placebo supplements ‘in-kind’, but made no financial contributions to the study. The authors disclose no financial interests or any other conflicts of interest.

References

- Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for measuring depression. *Archives of general psychiatry* 4, 561-571.
- Bozikas, V.P., Andreou, C., 2011. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. *The Australian and New Zealand journal of psychiatry* 45(2), 93-108.
- Coyle, J.T., 2012. NMDA receptor and schizophrenia: a brief history. *Schizophrenia bulletin* 38(5), 920-926.
- Dickerson, F.B., Brown, C.H., Kreyenbuhl, J.A., Fang, L., Goldberg, R.W., Wohlheiter, K., Dixon, L.B., 2006. Obesity among individuals with serious mental illness. *Acta psychiatrica Scandinavica* 113(4), 306-313.
- Gronier, B., Savignac, H.M., Di Meceli, M., Idriss, S., Tzortzis, G., DC, A., PWJ, B., 2018. Increased cortical neuronal responses to NMDA and improved attentional set-shifting performance in rats following prebiotic (B-GOS®) ingestion. *European Neuropsychopharmacology*. 28(1), 211-224
- Kao, A.C., Spitzer, S., Anthony, D.C., Lennox, B., Burnet, P.W.J., 2018. Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. *Translational psychiatry* 8(1), 66.
- Keefe, R.S., Harvey, P.D., Goldberg, T.E., Gold, J.M., Walker, T.M., Kennel, C., Hawkins, K., 2008. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). *Schizophrenia research* 102(1-3), 108-115.
- Savignac, H.M., Corona, G., Mills, H., Chen, L., Spencer, J.P., Tzortzis, G., Burnet, P.W., 2013. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. *Neurochemistry international* 63(8), 756-764.
- Schmidt, K., Cowen, P.J., Harmer, C.J., Tzortzis, G., Errington, S., Burnet, P.W., 2015. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. *Psychopharmacology* 232(10), 1793-1801.
- Vulevic, J., Juric, A., Tzortzis, G., Gibson, G.R., 2013. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. *The Journal of nutrition* 143(3), 324-331.

Figure 1





Figure 1: Effect of B-GOS® (n=24) and placebo (n=25) on composite T-score represented by (A) the change in T-Score before and after supplementation and (B) over the 24-week study. *p<0.05 with paired t-tests; #p<0.05 compared to baseline (week 0), with linear mixed model repeated measures.

Supplementary Information

Figure S1: Study flow chart






Figure S2: Effect of (A) B-GOS® and (B) placebo on T scores calculated separately for executive (digit sequencing, symbol coding, Tower of London) and verbal (verbal fluency, verbal memory) domains of the BACS. *p<0.05.

Table S1: Effect of B-GOS® on cognitive and metabolic measures (Olz = olanzapine; Clz= clozapine)

Parameter	Pre-BGOS (n = 24)	Post-BGOS (n = 24)	<i>t</i> (<i>p</i>)
	mean (SEM)	mean (SEM)	
Demographics			
Sex (% Female)	38%		
Age (years)	38.45 (2.417)		
Duration of Illness (years)	9.97 (1.830)		
Antipsychotic Medication (% Olz/Clz)	63%		
Ethnicity (% White)	75%		
Becks' Depression Index	10.04 (1.81)	10.04 (2.624)	0 .00 (1.00)
Central Adiposity			
Body Mass Index	32.32 (1.569)	32.63 (1.561)	-1.27 (0.217)
Waist-to-Hip Ratio	0.93 (0.011)	0.93 (0.011)	-0.59 (0.559)
Hip Circumference (cm)	112.83 (6.237)	121.46 (4.84)	-1.28 (0.214)
Waist Circumference (cm)	105.2 (6.069)	113.92 (5.177)	-1.36 (0.189)
Cognitive Tests			
Verbal Memory (T-score)	35.24 (2.132)	35.41 (2.215)	-0.10 (0.925)
Digit Sequencing (T-score)	35.86 (1.84)	36.9 (2.038)	-0.82 (0.423)
Verbal Fluency (T-score)	41.62 (2.191)	40.66 (1.657)	0.62 (0.542)
Symbol Coding (T-score)	37.18 (1.599)	38.72 (1.688)	-1.59 (0.127)
Tower of London (T-score)	46.45 (1.746)	49.1 (1.767)	-1.32 (0.200)
Composite Score (T-score)	33.83 (1.501)	36.17 (1.396)	-2.17 (0.040)*
Token Motor (Raw Score)	60.33 (5.828)	63.5 (6.245)	-0.79 (0.439)
Serum Markers			
Acetate (nmol/ml)	1881.47 (118.722)	1448.29 (140.946)	1.70 (0.102)
C-Reactive Protein (ng/ml)	4.54 (0.825)	3.89 (0.755)	1.51 (0.150)
IL-6 (pg/ml)	2.12 (0.451)	1.61 (0.448)	1.02 (0.320)

Table S2: Effect of placebo on cognitive and metabolic measures (Olz = olanzapine; Clz= clozapine)

Parameter	Pre-placebo (n = 25) mean (SEM)	Post-placebo (n = 25) mean (SEM)	<i>t</i> (<i>p</i>)
Demographics			
Sex (% Female)	40%		
Age (years)	38.80 (2.270)		
Duration of Illness (years)	9.74 (1.767)		
Antipsychotic Medication (% Olz/Clz)	56%		
Ethnicity (% White)	76%		
Becks' Depression Index	9.79 (1.629)	13.71 (2.815)	-1.88 (0.073)
Central Adiposity			
Body Mass Index	32.48 (1.533)	32.6 (1.476)	-0.44 (0.664)
Waist-to-Hip Ratio	0.93 (0.01)	0.94 (0.01)	-0.77 (0.452)
Hip Circumference (cm)	116.38 (3.357)	112.75 (6.008)	0.62 (0.54)
Waist Circumference (cm)	108.59 (3.402)	105.93 (5.862)	0.49 (0.629)
Cognitive Tests			
Verbal Memory (T-score)	31.71 (2.334)	34.89 (2.016)	-1.61 (0.122)
Digit Sequencing (T-score)	36.12 (1.839)	36.89 (1.907)	-0.54 (0.595)
Verbal Fluency (T-score)	40.84 (1.925)	43.88 (2.339)	-2.23 (0.035)*
Symbol Coding (T-score)	37.46 (1.604)	37.66 (1.824)	-0.17 (0.864)
Tower of London (T-score)	46.07 (2.072)	47 (1.74)	-0.41 (0.682)
Composite Score (T-score)	33.67 (1.519)	35.27 (1.699)	-1.31 (0.202)
Token Motor (Raw Score)	62.96 (6.839)	65.6 (6.734)	-0.69 (0.499)
Serum Markers			
Acetate (nmol/ml)	1690.37 (136.14)	1386.75 (61.494)	1.89 (0.071)
C-Reactive Protein (ng/ml)	4.78 (0.766)	5.08 (0.899)	-0.45 (0.658)
IL-6 (pg/ml)	2.15 (0.446)	1.77 (0.461)	0.67 (0.511)